---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019901"
form_type: "8-K"
ticker: "LFST"
cik: "0001845257"
company_name: "LifeStance Health Group, Inc."
filed_at: "2023-05-10T23:59:59+00:00"
generated_at: "2026-06-15T07:04:11.667606+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# LifeStance Q1 rev $252.6M (+24% YoY), net loss narrows to $34.2M; raises FY rev guidance

## Summary
- Revenue $252.6M (+24% YoY); Center Margin $69.6M (27.6% of revenue, +28% YoY).
- Net loss $34.2M vs $62.3M loss; Adj EBITDA $10.1M vs $12.5M (down 19%).
- FY 2023 revenue guidance raised to $990M-$1.02B; Center Margin $274-$290M; Adj EBITDA reaffirmed $50-$62M.
- Q2 2023 guidance: rev $250-$260M, Center Margin $69-$76M, Adj EBITDA $10-$16M.
- Clinicians 5,961 (+19% YoY, net add 330); cash $68.3M, net debt $224.8M.

## SEC filing metadata
- accession: 0000950170-23-019901
- form_type: 8-K
- ticker: LFST
- cik: 0001845257
- company_name: LifeStance Health Group, Inc.
- filed_at: 2023-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845257/000095017023019901/0000950170-23-019901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845257/000095017023019901/lfst-20230510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019901
- JSON: https://secwatch.observer/filing/0000950170-23-019901.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019901.txt

## Key facts
- Earnings Releases
  LifeStance Health Group, Inc. reported the first quarter ended March 31, 2023 results: revenue $252.6 million, net income $34.2 million. Guidance raised.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $252.6 million
  - Net income: $34.2 million
  - Guidance: raised
  - Result: reported results
  source text: the first quarter ended March 31, 2023. (All results compared to prior-year comparative period, unless otherwise noted) Q1 2023 Highlights and FY 2023 Outlook • Total revenue of $252.6 million increased $49.5 million or 24% compared to revenue of $203.1 million • Total clinicians of 5,961 up 19%, a sequential net increase of 330 in the first quarter • Net loss of $34.2
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845257/000095017023019901/0000950170-23-019901-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.